A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

Low- and middle-income countries are under-represented in research into the gut microbiome, and addressing this is key to understanding the link between gut-resident microorganisms and health.

Cancer Prevention Research publishes articles that focus on cancer prevention, preclinical, clinical, and translational research, with special attention given to molecular discoveries and an emphasis ...

Manufactured by Eli Lilly and Company, both Mounjaro and Zepbound contain the active ingredient tirzepatide. Tirzepatide is similar to semaglutide, which is used in medications like Ozempic, Rybelsus, ...

Further research is necessary to understand the potential ocular risks of semaglutide and tirzepatide. Bradley J. Katz, MD, PhD, and colleagues reported that ophthalmic complications were observed in ...

39,001 people played the daily Crossword recently. Can you solve it faster than others?39,001 people played the daily Crossword recently. Can you solve it faster than others?

Research has shown that Zepbound’s active ingredient, tirzepatide, is very effective for weight loss. You must have a prescription to get Zepbound. Without insurance, the Zepbound pen can cost ...

New tools and products developed by biotechnologists are useful in research, agriculture, industry and the clinic. Sustainable engraftment of heart muscle cells (cardiomyocytes) can be achieved by ...

Mounjaro (tirzepatide) is a prescription drug used to help manage blood sugar levels in adults with type 2 diabetes. Mounjaro comes as an injection that’s given under your skin. This medication ...

See which services passed our rigorous vetting process. Share on Pinterest Mounjaro (tirzepatide) is an injectable medication that’s approved for diabetes by the Food and Drug Administration (FDA).

A senior figure at the company operating the only sustainable aviation fuel (SAF) production plant in the UK has urged the government and industry “to be transparent” on the costs to consumers of ...

Eli Lilly has decided to wait for the readout of the second of its two phase 3 trials for tirzepatide in obesity, rather than filing on the strength of its first, positive study.